Cellular rejuvenation and aging research advancements

Research and clinical applications for cellular rejuvenation and biological aging management have seen significant progress. In August 2026, Life Biosciences began Phase 1 human clinical trials for ER-100, an experimental therapy aimed at reversing cellular aging through partial epigenetic reprogramming. This treatment uses three transcription factors—OCT4, SOX2, and KLF4—to modify gene activity in patients with specific ocular conditions, such as open-angle glaucoma.

Parallel advancements in the field include the development of senolytics to eliminate senescent cells and the use of mRNA therapies to reactivate telomeres. Research from Kyoto University has identified that the interaction between proteins PGAM1 and Chk1 supports the survival of senescent cells via a metabolic shift known as the ‘Pseudo-Warburg effect’. Preclinical studies using the compound Nutlin 3b have successfully disrupted this interaction to remove senescent cells in mice. The integration of epigenetic resetting, senolysis, and autophagy activation marks a shift toward treating aging as a manageable cellular dysfunction.